NCT00471666

Medical Implications of Coinfection With Malaria and Filariasis Parasites

Completed Last updated 2 July 2017

What this trial tests

trial in Malaria in 1,039 participants. Completed in 31 January 2012.

Timeline

7 May 2007

31 January 2012

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,039
Start date	7 May 2007
Estimated completion	31 January 2012
Sites	1 location across Mali

Conditions studied

• Malaria — all drugs for Malaria →
• Filariasis — all drugs for Filariasis →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 1 to 20, any sex, with Malaria or Filariasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine the clinical, immunological and epidemiological effects of concurrent infections with P. falciparum and W. bancrofti or M. perstans (the parasites that cause malaria and filariasis) on the frequency and severity of malaria infection in children and young adults in Mali, Africa.

Residents of Tien gu bougou and Bougoudiana, Mali, who are between 1 and 20 years of age may be eligible for this study. Participants with and without filarial infection will be enrolled.

Participants undergo the following tests and procedures:

* Baseline evaluation with medical history and physical examination, blood tests and stool culture
* Brief physical examinations weekly
* Blood tests monthly for malaria
* Standard treatment offered for anyone with malaria
* Blood tests for filarial infection at the beginning, midpoint and end of the transmission season
* Treatment for lymphatic filariasis is available through the National Program for the Elimination of Lymphatic Filariasis. There is no effective standard therapy for M. perstans.
* Treatment for other parasitic worm infections, if needed.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. At homeostasis filarial infections have expanded adaptive T regulatory but not classical Th2 cells.
   Metenou S, Dembele B, Konate S, Dolo H, et al · · 2010 · cited 93× · PMID 20357251 · DOI 10.4049/jimmunol.0904067
2. Filarial infection suppresses malaria-specific multifunctional Th1 and Th17 responses in malaria and filarial coinfections.
   Metenou S, Dembele B, Konate S, Dolo H, et al · · 2011 · cited 57× · PMID 21411732 · DOI 10.4049/jimmunol.1003778
3. Patent filarial infection modulates malaria-specific type 1 cytokine responses in an IL-10-dependent manner in a filaria/malaria-coinfected population.
   Metenou S, Dembélé B, Konate S, Dolo H, et al · · 2009 · cited 54× · PMID 19561105 · DOI 10.4049/jimmunol.0900257
4. Filariasis attenuates anemia and proinflammatory responses associated with clinical malaria: a matched prospective study in children and young adults.
   Dolo H, Coulibaly YI, Dembele B, Konate S, et al · · 2012 · cited 45× · PMID 23133692 · DOI 10.1371/journal.pntd.0001890
5. The complete mitochondrial genome sequence of the filarial nematode Wuchereria bancrofti from three geographic isolates provides evidence of complex demographic history.
   Ramesh A, Small ST, Kloos ZA, Kazura JW, et al · · 2012 · cited 45× · PMID 22326389 · DOI 10.1016/j.molbiopara.2012.01.004
6. Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-γ in filaria-malaria co-infection.
   Metenou S, Kovacs M, Dembele B, Coulibaly YI, et al · · 2012 · cited 26× · PMID 22213332 · DOI 10.1002/eji.201141991
7. Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection.
   Metenou S, Coulibaly YI, Sturdevant D, Dolo H, et al · · 2014 · cited 13× · PMID 24737144 · DOI 10.1002/eji.201444452